enGene Holdings Inc. (ENGN), a company engaged in developing genetic medicines at the clinical stage, announced on Monday the appointment of Joan Connolly as Chief Technology Officer. Connolly will also join the corporate leadership team in this capacity.
Furthermore, Anthony Cheung, Co-Founder and former Chief Technology Officer of enGene, will take on the new role of Chief Scientific Officer, a position previously held by James Sullivan.
Joan Connolly brings to enGene over 30 years of experience in Chemistry, Manufacturing, and Controls (CMC) development, encompassing both large and small molecules. Her expertise spans manufacturing management, regulatory submissions, product commercialization, as well as supply chain and logistics, sourcing, and procurement.
Prior to joining enGene, Connolly held the position of Chief Technology Officer at Albireo Pharma, Inc. She has also occupied senior roles at Stemline Therapeutics, Inc., ImClone Systems Inc., and Bristol-Myers Squibb.
Ron Cooper, the Chief Executive Officer of enGene, remarked, "Joan's substantial experience in managing the technical operations essential for guiding a late-stage clinical asset to commercialization will be invaluable. This expertise is especially crucial as we aim to complete the pivotal stage of the LEGEND study of detalimogene and plan to submit our Biologics License Application (BLA) by mid-2026."
